{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:27:59Z","timestamp":1789003679469,"version":"build-2803163510"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["296306"],"award-info":[{"award-number":["296306"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.atherosclerosis.2024.117523","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T08:46:30Z","timestamp":1710578790000},"page":"117523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-1948","authenticated-orcid":false,"given":"Paolo","family":"Raggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovana","family":"Milic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Manicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Cinque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.117523_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jhep.2020.08.028","article-title":"The times they are a-changin\u2019 (for NAFLD as well)","volume":"73","author":"Ratziu","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.746151","article-title":"Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites","volume":"12","author":"Russo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"2019","key":"10.1016\/j.atherosclerosis.2024.117523_bib9","first-page":"e563","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117523_bib10","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.048884","article-title":"Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH","volume":"14","author":"Bravo","year":"2021","journal-title":"Dis Model Mech"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117523_bib11","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.3390\/ijms22126468","article-title":"Atorvastatin modulates bile acid homeostasis in mice with diet-induced nonalcoholic steatohepatitis","volume":"22","author":"Lastuvkova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112834","article-title":"Atorvastatin and vitamin E accelerates NASH resolution by dietary intervention in a preclinical Guinea pig model","volume":"11","author":"Klaebel","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4254\/wjh.v14.i1.119","article-title":"Is there a role of lipid-lowering therapies in the management of fatty liver disease?","volume":"14","author":"Tzanaki","year":"2022","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1570161118666201015152921","article-title":"Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?","volume":"19","author":"Sfikas","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/CLD.0000000000000015","article-title":"Review of the role of statins in cirrhosis and portal hypertension","volume":"22","author":"Gratac\u00f3s-Gin\u00e8s","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cgh.2022.01.057","article-title":"Statin Use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease","volume":"21","author":"Zou","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cgh.2021.03.031","article-title":"Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH Study","volume":"20","author":"Thomson","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep4.1241","article-title":"Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality","volume":"2","author":"Shahab","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijcard.2018.05.087","article-title":"The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe","volume":"270","author":"Simon","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1028355","article-title":"Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome","volume":"9","author":"Biolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","article-title":"Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial","volume":"13","author":"Lalwani","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in LDLr(-\/-) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38564","article-title":"Lysosomal cholesterol export reconstituted from fragments of Niemann-Pick C1","volume":"7","author":"Trinh","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib33","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc09-1765","article-title":"Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet","volume":"33","author":"Chan","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008953","article-title":"PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review","volume":"7","author":"Handelsman","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib39","article-title":"Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis","volume":"1865","author":"Emma","year":"2020","journal-title":"Biochim Biophys Acta - Mol Cell Biol Lipids"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","article-title":"Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis","volume":"77","author":"Paquette","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib41","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1074\/jbc.RA119.008094","article-title":"Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice","volume":"294","author":"Lebeau","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","article-title":"Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population","volume":"278","author":"Wargny","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5114\/pg.2023.126054","article-title":"Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review","volume":"18","author":"Jakielska","year":"2023","journal-title":"Gastroenterol Rev Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib44","first-page":"321","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOL.0000000000000663","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease","volume":"31","author":"Welty","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib46","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamacardio.2020.5341","article-title":"Genetic inhibition of PCSK9 and liver function","volume":"6","author":"Rimbert","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib48","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib49","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"2022","key":"10.1016\/j.atherosclerosis.2024.117523_bib52","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib54","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib55","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib56","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib57","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","article-title":"Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes","volume":"22","author":"Johansson","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib59","first-page":"185","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis","author":"He","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.101876","article-title":"Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Sun","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib61","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/dom.14054","article-title":"Efficacy, safety and cardiovascular outcomes of once\u2010daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme","volume":"22","author":"Thethi","year":"2020","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2024.117523_bib63","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib64","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib65","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib67","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra","year":"2022","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib68","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic to Transl Sci"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib69","unstructured":"The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis. [https:\/\/clinicaltrials.gov\/study\/NCT04822181?cond=; last accessed March 4, 2024]."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib70","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib71","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 Receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib72","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091111","article-title":"Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity","volume":"9","author":"Woo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib74","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Lin","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/JOE-16-0142","article-title":"Metformin increases hepatic leptin receptor and decreases steatosis in mice","volume":"230","author":"Tang","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107747","article-title":"Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years","volume":"35","author":"Lee","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24610","article-title":"Metformin exerts anti-liver fibrosis effect based on the regulation of gut microbiota homeostasis and multi-target synergy","volume":"10","author":"Kong","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108683","article-title":"Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin","volume":"108","author":"Su","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.biopha.2017.03.079","article-title":"Metformin mitigates carbon tetrachloride-induced TGF-\u03b21\/Smad3 signaling and liver fibrosis in mice","volume":"90","author":"Fan","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2023.106375","article-title":"Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis","volume":"157","author":"Su","year":"2023","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Della Pepa","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib82","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117523_bib83","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3390\/biomedicines10071487","article-title":"The determinants of liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"10","author":"Dai","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib84","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/1440-1681.13750","article-title":"Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: an umbrella systematic review and meta-analysis","volume":"50","author":"Musazadeh","year":"2023","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5805398","article-title":"Liver protective effect of fenofibrate in NASH\/NAFLD animal models","volume":"2022","author":"Mahmoudi","year":"2022","journal-title":"PPAR Res."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib87","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","article-title":"Lifestyle modification in NAFLD\/NASH: facts and figures","volume":"1","author":"Hallsworth","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib88","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Chalasani","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib89","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib90","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib91","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin E in the treatment of NAFLD","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib92","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib93","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QAD.0000000000002412","article-title":"Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients","volume":"34","author":"Sebastiani","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib94","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.freeradbiomed.2021.11.027","article-title":"Interventional study with vitamin E in cardiovascular disease and meta-analysis","volume":"178","author":"Violi","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib96","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1989.tb14926.x","article-title":"Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology","volume":"570","author":"Gey","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib97","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1989.tb14928.x","article-title":"Low plasma vitamins E and C. Increased risk of angina in Scottish men","volume":"570","author":"Riemersma","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib98","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/j.ijcard.2013.04.142","article-title":"Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation","volume":"168","author":"Cangemi","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib99","first-page":"930","article-title":"Lower ischemic heart disease incidence and mortality among vitamin supplement users","volume":"12","author":"Meyer","year":"1996","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajcn\/64.2.190","article-title":"Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly","volume":"64","author":"Losonczy","year":"1996","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.294.1.56","article-title":"Vitamin E in the primary prevention of cardiovascular disease and cancer; the Women's Health Study: a randomized controlled trial","volume":"294","author":"Lee","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib102","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(96)90866-1","article-title":"Randomised controlled trial of vitamin E in patients with coronary disease: cambridge Heart Antioxidant Study (CHAOS)","volume":"347","author":"Stephens","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib103","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib104","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/archinte.158.6.668","article-title":"Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease","volume":"158","author":"Virtamo","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice","volume":"357","author":"Roncaglioni","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib106","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.2008.600","article-title":"Vitamins E and C in the prevention of cardiovascular disease in men: the physicians' health study II randomized controlled trial","volume":"300","author":"Sesso","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib107","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM200001203420302","article-title":"Vitamin E supplementation and cardiovascular events in high-risk patients","volume":"342","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)09328-5","article-title":"MRC\/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib109","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials","volume":"341","author":"Sch\u00fcrks","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/svn-2020-000519","article-title":"Effects of vitamin E on stroke: a systematic review with meta-analysis and trial sequential analysis","volume":"6","author":"Loh","year":"2021","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib111","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1158\/1055-9965.EPI-09-0013","article-title":"Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial","volume":"18","author":"Neuhouser","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib112","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: an update","volume":"78","author":"Upadhyay","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib113","first-page":"13","article-title":"Pioglitazone: mechanism of action","author":"Smith","year":"2001","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib114","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib116","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta\u2010analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib117","article-title":"Pioglitazone on nonalcoholic steatohepatitis: a systematic review and meta-analysis of 15 RCTs","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000481","article-title":"Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study","volume":"6","author":"Strongman","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib119","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1185\/03007995.2014.941054","article-title":"A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study","volume":"30","author":"Yang","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib120","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib121","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","article-title":"Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials","volume":"16","author":"de Jong","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib122","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib123","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib124","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib125","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib126","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib127","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib128","unstructured":"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stag. [https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04849728; last accessed March 4, 2024]."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2007.04.013","article-title":"Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis","volume":"47","author":"Balas","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.1183","article-title":"Nonalcoholic fatty liver disease: the role of visceral adipose tissue","volume":"19","author":"Hanlon","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib131","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib132","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib133","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117523_bib134","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib135","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(23)00440-3","article-title":"Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.117523_bib136","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024000832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024000832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T15:59:05Z","timestamp":1716134345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024000832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":136,"alternative-id":["S0021915024000832"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117523","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117523"}}